Abstract Disease Overview Primary myelofibrosis (PMF) is a myeloproliferative neoplasm
(MPN) characterized by stem cell‐derived clonal myeloproliferation that is often but not …

Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only curative
approach in myelofibrosis (MF). Despite advances over recent decades, relapse and non …

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …

Abstract JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the
impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell …

Primary myelofibrosis (PMF) is one of three myeloproliferative neoplasms (MPN) that are
morphologically and molecularly inter-related, the other two being polycythemia vera (PV) …

Splenomegaly is a hallmark of myelofibrosis, a debilitating haematological malignancy for
which the only curative option is allogeneic haematopoietic cell transplantation (HCT) …

The number of patients with myelofibrosis (MF) undergoing an allogeneic hemopoietic stem
cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood …

To develop a prognostic model for patients undergoing allogeneic hematopoietic cell
transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients …

New options for medical therapy and risk scoring systems containing molecular data are
leading to increased complexity in the management of patients with myelofibrosis. To inform …

Momelotinib for myelofibrosis: 12-year survival data and retrospective comparison to
ruxolitinib Momelotinib for myelofibrosis: 12-year survival data and retrospective …